|
|
http://app.quotemedia.com/data/...change+Act&dateFiled=2016-10-28
Altlasten sind noch da.
The warrants will have an exercise price of US$4.70 per share
~ MACRILEN™ (macimorelin) Product Launch on Track for July 2018 ~
The first quarter of 2018 was highly productive for Strongbridge as we began preparing for the commercial launch in July of MACRILEN™ (macimorelin), the first and only FDA-approved oral drug indicated for the diagnosis of Adult Growth Hormone Deficiency (AGHD). The interest from the endocrinology community across the United States has been significant; the enthusiasm to adopt a safe, simple and accurate drug to use in their assessment of AGHD has reinforced our optimism about the market potential for MACRILEN,” said Matthew Pauls, president and chief executive officer of Strongbridge Biopharma.
http://investors.strongbridgebio.com/...-first-quarter-2018-financial
|
Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
25 | 17.117 | Aeterna nach dem Split | Heron | Hbit | 25.11.23 10:08 | |
9 | 13.769 | AEZS vs. KERX | Gropius | paioneer | 03.09.22 18:22 | |
19 | Wie geht's jetzt weiter mit Aeterna Zentaris? | Ebi52 | Bullish_Hope | 03.08.22 00:11 | ||
21 | 7.680 | Aeterna Zentaris Inc. | Heron | Heron | 30.09.21 23:37 | |
2 | 62 | AEterna Zentaris (AEZS)- Reboundkandidat?? | Vollzeittrader | marroni | 25.04.21 13:13 |